Browse a selection of key resources and publications about our pipeline.

CLN-978, a Novel Half-Life Extended CD19/CD3/HSA-Specific T Cell-Engaging Antibody Construct With Potent Activity Against B-Cell Malignancies With Low CD19 Expression (2023 JITC)

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions (2023 JCO)

Phase 1/2a Study of CLN-081 in NSCLC Patients with EGFR Exon 20 Insertion (ex20ins) Mutations (2022 ASCO)

CLN-049 is a Bispecific T Cell-Engaging, IgG-Like Antibody Targeting FLT3 on AML Cells (2022 AACR)

Preclinical Characterization of a Next-Generation CD19/CD3-Bispecific T Cell Engaging Antibody Construct CLN-978 With Long Serum Half-Life and Superior Potency Against Target Cells Expressing Very Low Levels of CD19 (2022 AACR)

A Novel IgG-Based FLT3xCD3 Bispecific Antibody for the Treatment of AML and B-ALL (2022 JITC)

Safety and Activity of CLN-081 (TAS6417) in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (2021 ASCO)

Preliminary Safety and Activity of CLN-081 in NSCLC With EGFR Exon 20 Insertion Mutations (Ins20) (2020 ESMO)

Multicenter Phase 1/2a trial of CLN-081 (TAS6417) in NSCLC Patients with EGFR Exon 20 Insertion Mutations (2019 WCLC)